PATIENT REGISTRY ANNUAL DATA REPORT

1 PATIENT REGISTRY 2020 ANNUAL DATA REPORTPATIENT REGISTRY ANNUAL DATA REPORT 2020 cystic FIBROSIS FOUNDATIONMISSION OF THE cystic FIBROSIS FOUNDATIONThe mission of the cystic Fibrosis Foundation is to cure cystic fibrosis and to provide all people with the disease the opportunity to lead full, productive lives by funding research and drug development, promoting individualized treatment, and ensuring access to high-quality, specialized OF DATA cystic fibrosis patients under care at CF Foundation-accredited care centers in the United States, who consented to have their data entered.

2 SUGGESTED CITATIONC ystic Fibrosis Foundation PATIENT Registry2020 ANNUAL Data REPORT Bethesda, Maryland 2021 cystic Fibrosis Foundation FIGURE PERMISSIONSTo request use of charts and data provided in this REPORT , contact the CF Foundation PATIENT REGISTRY team by email at BYDennis O ClairFelipe Ruiz MendozaCourtesy of the Russell familySPECIAL ACKNOWLEDGMENTST hose who contributed to the maintenance of PortCF, analysis of data, and creation of this REPORT : Bruce MarshallAlbert FaroWhitney BrownAlexander ElbertAliza FinkElizabeth CromwellJosh OstrengaKristofer Petren Michelle YuthOlga DorokhinaRunyu WuSamar RizviThomas O NeilAnnual Data REPORT 2020 cystic Fibrosis Foundation PATIENT REGISTRY 1 September 2021 Dear Friends and Colleagues:We are pleased to share the 2020 PATIENT REGISTRY ANNUAL Data REPORT .

3 The impact of two significant events is visible in this REPORT : first, the impact of the COVID-19 pandemic and, second, the availability of elexacaftor/tezacaftor/ivacaftor (ETI) to many more people with cystic fibrosis (CF). The delivery of CF care was dramatically impacted by the pandemic as indicated by the dramatic shift to telehealth in March 2020 and the continuation of telehealth visits throughout the year. On a positive note, lost to follow-up remained low at percent, demonstrating the resilience of the CF community. One caveat the pandemic resulted in less REGISTRY data than in past years, and that may affect some of our findings.

4 For example, fewer microbiology cultures were collected, and that may have contributed to the lower annualized prevalence of potential microbial pathogens. Also, fewer pulmonary function measurements were collected, and some were from home spirometers. These factors may have impacted the precision of the annualized values of FEV1. I strongly encourage you to read the About This REPORT chapter in which some of these considerations are of the positive trends in clinical metrics are almost certainly in part attributable to the second significant event in 2020, the prescription of ETI to many more people with CF.

5 For example, the data showed a decrease in ANNUAL mortality rate ( per 100 people in 2020 as compared to per 100 people in 2010). We also observed significant decreases in the proportion of people with CF treated with IV antibiotics for a pulmonary exacerbation and in the number of people with CF who underwent a lung transplantation. One surprising observation is the marked increase in the number of pregnancies in 2020. While ETI likely contributed to many of these trends, it is difficult to tease out potential confounding by the pandemic and other factors.

6 Further research will be thanks to each and every one of you who contribute to the success of the REGISTRY most importantly, people with CF and their families who generously agree to share their data and the REGISTRY coordinators and care team members who collect and enter the data. It would not be possible without your vital you all for your hard work throughout the year and your commitment to the CF Foundation s mission. Bruce C. Marshall.

7 MD Executive Vice President and Chief Medical Officer cystic Fibrosis FoundationCystic Fibrosis Foundation PATIENT REGISTRY ANNUAL Data REPORT 20202 TABLE OF CONTENTSABOUT THIS REPORT 5 INTRODUCTION 6 Changes to PortCF in 2020 6 Use of Telehealth in Delivery of CF Care 7 Coverage of Care in 2020 7 Summary 9 DEMOGRAPHICS 12 Characteristics of Adults with CF 14 Health Insurance Information 16 DIAGNOSIS 17 Diagnostic Characteristics of Individuals with CF 17 Diagnostic Tests 20 CFTR GENE VARIANTS 22 GUIDELINES.

8 CARE, SCREENING, AND PREVENTION 26 PATIENT Care Guidelines 26 Infant Care Guidelines 29 MICROBIOLOGY 32 Pseudomonas aeruginosa 34 Staphylococcus aureus 35 Nontuberculous Mycobacteria 36 NUTRITION 38 Infant Feeding 42 PULMONARY AND NUTRITIONAL OUTCOMES 43 PULMONARY FUNCTION 45 Pulmonary Exacerbations 48

9 THERAPIES 50 CFTR Modulator Therapies 50 Pulmonary Therapies 53 Gastrointestinal (GI) Therapies 60 ANNUAL Data REPORT 2020 cystic Fibrosis Foundation PATIENT REGISTRY 3 COMPLICATIONS 62CF Complications by Age, 2020 64 cystic Fibrosis-Related Diabetes (CFRD) 66 Depression and Anxiety 69 TRANSPLANTATION 71 Lung Transplantation 71 SURVIVAL 74 Median Predicted Survival 74 Median Conditional Predicted Survival 75 Mortality Rate 75 Median Age at Death 76 Causes of Death 76CF FOUNDATION PATIENT REGISTRY QUESTIONNAIRE 77 REFERENCES

10 92 cystic Fibrosis Foundation PATIENT REGISTRY ANNUAL Data REPORT 20204 ANNUAL Data REPORT 2020 cystic Fibrosis Foundation PATIENT REGISTRY 5 ABOUT THIS REPORTThe ANNUAL Data REPORT is based on data entered in the CF Foundation PATIENT REGISTRY through our online portal, PortCF . Data are entered by teams of dedicated health professionals in our nationwide network of more than 120 CF Foundation-accredited Care CriteriaThis ANNUAL Data REPORT contains data from individuals diagnosed with CF who (a) have consented to participate in the REGISTRY , and (b) were seen in a CF Care Center during the 2020 calendar year, including those who were born, diagnosed, or died in the year.